Patents by Inventor Bal Ram Singh

Bal Ram Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220226282
    Abstract: The present invention relates to a method of treating an individual suffering from botulism comprising administering to the individual a composition comprising a therapeutically effective amount of Compound 1 or its pharmaceutically acceptable salts or derivatives thereof.
    Type: Application
    Filed: January 18, 2021
    Publication date: July 21, 2022
    Inventors: Bal Ram Singh, Kruti Patel
  • Patent number: 11389497
    Abstract: Presently claimed invention related to a pharmaceutical composition comprising ascorbic acid caffeoylquinic acid, rosmarinic acid. and glycosyl sulfones obtained from Ocimum Sanctum and a process for isolating said composition from Ocimum Sanctum. Presently claimed invention also provides a method of treating neural crest derived tumors such as malignant neurofibroma and melanoma.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: July 19, 2022
    Assignee: Prime Bio, Inc.
    Inventors: Bal Ram Singh, Chandra K Mayanil, Tadanori Tomita, Raj Kumar
  • Publication number: 20220081473
    Abstract: Present invention relates to a pharmaceutical composition comprising P80 with drugs, dyes, small molecules, biomolecules, proteins or combination thereof. P80 enhances the transportation of molecules associated with it. The P80 is a tight junction modulators to enhance the permeability of the intestinal epithelium so as to facilitate drug delivery. The invention further provides a process for the preparation, isolation and purification of p80 protein.
    Type: Application
    Filed: September 17, 2020
    Publication date: March 17, 2022
    Applicant: Prime Bio, Inc
    Inventors: Bal Ram Singh, Raj Kumar
  • Publication number: 20210346292
    Abstract: The main aspect of present invention is to provide a pharmaceutical composition to increase the stability of liquid formulation of botulinum toxin and related proteins. The present invention provides a method to stabilize toxin in liquid formulation. Lipid based drug delivery system is known to increase the bioavailability of drugs (Amidon et al., 1995; Jannin et al., 2008). We investigated the stability of BoNT/A toxin and complex. We used two formulations in liquid phase: combination of lipids and liposomes, with two different storage conditions: 4° C. and 25° C. The present invention also provides a method for efficient delivery of botulinum toxin through skin as a topical application.
    Type: Application
    Filed: May 6, 2020
    Publication date: November 11, 2021
    Applicant: Prime Bio, Inc.
    Inventors: Bal Ram Singh, Raj Kumar, Boke Zhang
  • Patent number: 11040090
    Abstract: Present invention provides a stable pharmaceutical composition comprising botulinum neurotoxin, anesthetic in a buffer. Present invention also provides a process for the preparation of the stable pharmaceutical composition. The botulinum neurotoxin is stabilized by the formation of complex between the toxin and anesthetic. The present invention further provides a method for treating wrinkles using the said pharmaceutical composition.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: June 22, 2021
    Assignee: Prime Bio, Inc
    Inventor: Bal Ram Singh
  • Publication number: 20210121542
    Abstract: The present invention relates to a composition for the delivery of drug molecules, especially therapeutic proteins via oral route, sublingual, and buccal routes. The embodiments herein provide delivery of therapeutic proteins with the help of neurotoxin associated proteins (NAPs) from Clostridium botulinum type A or type E. The NAPs combine with proteins and/or drug molecules to form a composition for oral or sublingual delivery.
    Type: Application
    Filed: October 28, 2020
    Publication date: April 29, 2021
    Inventors: Bal Ram Singh, Raj Kumar, Kruti Patel
  • Publication number: 20210023158
    Abstract: Presently claimed invention related to a pharmaceutical composition comprising ascorbic acid, caffeoylquinic acid, rosmarinic acid. and glycosyl sulfones obtained from Ocimum Sanctum and a process for isolating said composition from Ocimum Sanctum. Presently claimed invention also provides a method of treating neural crest derived tumors such as malignant neurofibroma and melanoma.
    Type: Application
    Filed: April 16, 2020
    Publication date: January 28, 2021
    Inventors: Bal Ram Singh, Chandra Shekhar K Mayanil, TADANORl TOMITA, Raj Kumar
  • Publication number: 20190076518
    Abstract: The present invention describes a neurotoxin associated protein from botulinum neurotoxin complex used as an oral or nasal delivery system for a vaccine. The vaccine is selected from tetanus, diphtheria and pertussis alone or in combination. Further the oral or nasal delivery of tetanus vaccine in combination with other drug molecules.
    Type: Application
    Filed: March 9, 2016
    Publication date: March 14, 2019
    Inventor: Bal Ram Singh
  • Publication number: 20180161406
    Abstract: Present invention provides a stable pharmaceutical composition comprising botulinum neurotoxin, anesthetic in a buffer. Present invention also provides a process for the preparation of the stable pharmaceutical composition. The botulinum neurotoxin is stabilized by the formation of complex between the toxin and anesthetic. The present invention further provides a method for treating wrinkles using the said pharmaceutical composition.
    Type: Application
    Filed: December 8, 2016
    Publication date: June 14, 2018
    Applicant: Prime Bio, Inc
    Inventor: Bal Ram Singh
  • Publication number: 20180147223
    Abstract: Present invention discloses a method of treating an individual suffering from botulism by inhibiting botulinum neurotoxins.
    Type: Application
    Filed: November 29, 2016
    Publication date: May 31, 2018
    Applicant: Prime Bio, Inc
    Inventors: Bal Ram Singh, Kruti Patel
  • Publication number: 20160051644
    Abstract: The present invention relates to the isolation of polypeptides derived from the Clostridium botulinum neurotoxin and the use thereof as treatment for neuronal injury such as spinal cord injury. Botulinum neurotoxin binds to neural cells and are translocated into the cytosol and therefore is useful as a target specific therapeutic delivery system. Non-toxic botulinum toxin may be created by light chain mutagenesis and/or removal of the endopeptidase domain.
    Type: Application
    Filed: January 16, 2014
    Publication date: February 25, 2016
    Inventor: Bal Ram Singh
  • Patent number: 9139624
    Abstract: An isolated, biologically active 33 kDa hemagglutinin purified from the type A Clostridium botulinum neurotoxin complex and its uses are described.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: September 22, 2015
    Assignee: Bal Ram Singh
    Inventors: Bal Ram Singh, Shashi Kant Sharma
  • Publication number: 20150010535
    Abstract: This application is based, inter alia, on the discovery of a binding interaction between the Hn-33 hemagglutinin polypeptide of the type A Clostridium botulinum neurotoxin complex and synaptosomal proteins, including synaptotagmin II (Syt II). Methods of screening for compounds that modulate, e.g., increase or decrease, this interaction are provided. Also provided are compositions and methods for targeting compounds to neuronal and cancer cells by coupling the compounds to Hn-33 or biologically active Hn-33 variants.
    Type: Application
    Filed: May 19, 2014
    Publication date: January 8, 2015
    Inventor: Bal Ram Singh
  • Patent number: 8748106
    Abstract: This application is based, inter alia, on the discovery of a binding interaction between the Hn-33 hemagglutinin polypeptide of the type A Clostridium botulinum neurotoxin complex and synaptosomal proteins, including synaptotagmin II (Syt II). Methods of screening for compounds that modulate, e.g., increase or decrease, this interaction are provided. Also provided are compositions and methods for targeting compounds to neuronal and cancer cells by coupling the compounds to Hn-33 or biologically active Hn-33 variants.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: June 10, 2014
    Inventors: Bal Ram Singh, Yu Zhou
  • Patent number: 8586081
    Abstract: The present invention relates to the isolation of polypeptides derived from the Clostridium botulinum neurotoxin and the use thereof as immunogens for the production of vaccines and antitoxins, as well as research and drug development applications. Clostridium botulinum is responsible for food bone botulism, a severe and often deadly disease. Botulinum neurotoxin binds to neural cells and are translocated into the cytosol. The toxin then prevents neurotransmitter release by cleaving a SNARE protein. A double mutant E224A/E262 full length botulinum neurotoxin Type A holo form was successfully cloned and purified, which lacks the endopeptidase activity involved in the toxic action of the BoNT, and thus leading to its detoxification (DR BoNT/A). This new molecule can be used as an antidote against botulism, and also as a vaccine candidate for botulism. Due to the poor availability and extreme toxicity of native holo-toxin, a nontoxic form of the holo-toxin is highly desired for research and vaccine development.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: November 19, 2013
    Assignee: University of Massachusetts
    Inventors: Bal Ram Singh, Weiping Yang
  • Publication number: 20120171247
    Abstract: The invention features a polypeptide complex synthesized by bacteria of the genus Clostridia that contains the serotype E botulinum neurotoxin and five neurotoxin associated polypeptides having molecular weights of about 118, 80, 65, 40, and 18 kDa, respectively. The complex is useful in the treatment of diseases or conditions that are caused by excessive release of acetylcholine from presynaptic nerve terminals.
    Type: Application
    Filed: July 18, 2011
    Publication date: July 5, 2012
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: Bal Ram Singh, Zhong Zhang
  • Patent number: 7981432
    Abstract: The invention features a polypeptide complex synthesized by bacteria of the genus Clostridia that contains the serotype E botulinum neurotoxin and five neurotoxin associated polypeptides having molecular weights of about 118, 80, 65, 40, and 18 kDa, respectively. The complex is useful in the treatment of diseases or conditions that are caused by excessive release of acetylcholine from presynaptic nerve terminals.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: July 19, 2011
    Assignee: University of Massachusetts
    Inventors: Bal Ram Singh, Zhong Zhang
  • Publication number: 20100222254
    Abstract: A stable composition including a non-covalent complex of a botulinum neurotoxin and a cyclodextrin and a method of preserving botulinum neurotoxin and for producing a botulinum neurotoxin composition with improved stability properties in an efficient and economically advantageous manner. The invention seeks to alleviate the problems associated with rapid degradation or denaturation of botulinum neurotoxin by providing a novel composition that exhibits improved stability properties. The botulinum neurotoxin is preferably stabilized by forming a cyclodextrin complex.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Inventors: Bal Ram Singh, Andrew M. Ress
  • Patent number: 7744904
    Abstract: A stable composition including botulinum neurotoxin and a cyclodextrin and a method of preserving botulinum neurotoxin and for producing a botulinum neurotoxin composition with improved stability properties in an efficient and economically advantageous manner. The invention seeks to alleviate the problems associated with rapid degradation or denaturation of botulinum neurotoxin by providing a novel composition that exhibits improved stability properties. The botulinum neurotoxin is preferably stabilized by forming a cyclodextrin inclusion complex.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: June 29, 2010
    Assignee: B.B. Scientific L.L.C.
    Inventors: Bal Ram Singh, Andrew M. Ress
  • Publication number: 20100062024
    Abstract: An isolated, biologically active 33 kDa hemagglutinin purified from the type A Clostridium botulinum neurotoxin complex and its uses are described.
    Type: Application
    Filed: May 11, 2009
    Publication date: March 11, 2010
    Inventors: Bal Ram Singh, Shashi Kant Sharma